新浪登录
腾讯登录Epic Science和Upenn合作研究单细胞液体活检技术
| 导读 | Epic Science和宾夕法尼亚大学拉姆森癌症中心近日宣布进行合作，一起合作寻找循环肿瘤细胞的生物标记物。 |
根据双方的协议，双方将在多项单细胞分析循环肿瘤细胞（CTCs）的研究中进行合作，一起寻找能够对癌症治疗进行预测的生物标记物。拉姆森癌症研究中心的研究人员将使用Epic Science的“细胞掉队”CTC检测平台来研究不同类型癌症的异质性，并争取发现基因组和表型标记物之间的异质性，这些异质性能够帮助我们理解，肿瘤是如何变化的，以及这些肿瘤对现有疗法和新疗法应答会是怎样的。
“成功的治疗癌症，主要依赖于对病人肿瘤负荷的异质性，以及推动疾病进展背后的基因变化的了解，” Epic Science CEO Murali Prahalad在申明中这样说。该公司的CTC检测平台能够在一轮轮疗法和药物应答中，定量检测蛋白质组和基因组在肿瘤细胞中的积聚变化。该方法能够帮助评估药物耐药性的早期标志，并有可能影响治疗的选项，这其中也包括了联合疗法的使用。Epic Sciences已经和几个组织进行了合作，以使用其CTC技术来支持临床实验，并驱动其平台获得监管批准。今年7月，该公司签署了一项协议，使其CTC即使可以在亚洲的美国实验室公司使用，以支持其临床实验。今年5月，该公司与Prostate Cancer Clinical Trial Consortium合作，使其技术可以在前列腺癌实验中使用。
原文链接：
Epic Sciences and the University of Pennsylvania's Abramson Cancer Center today announced a collaboration to find biomarkers in circulating tumor cells.Under the terms of the agreement, the partners will conduct multiple studies analyzing circulating tumor cells (CTCs) at single-cell resolution to find biomarkers that are predictive of response to cancer treatments. Researchers at the Abramson Cancer Center will use Epic Sciences' "no cell left behind" CTC detection platform to study heterogeneity in different cancer types and find genomic and phenotypic markers to understand how tumors change and how they respond to existing and new therapies.
"Successful treatment of cancer depends on understanding the heterogeneity of the patient's tumor burden and the driving genetic alterations behind disease progression," Epic Sciences CEO Murali Prahalad said in a statement. The firm's CTC detection platform can quantify both proteomic and genomic changes that accumulate in tumor cells, over time and in response to successive rounds of therapy. The approach could help evaluate early signs of drug resistance and has the potential to influence therapy selection, including the use of combination therapies, the firm said in a statement.
Epic Sciences has partnered with several organizations to support clinical trials with its CTC technology as it drives towards regulatory approval of the platform. In July, the firm signed a deal to make its CTC technology available to Laboratory Corporation of America to support clinical trials in Asia. In May, the firm linked up with the Prostate Cancer Clinical Trial Consortium to provide its technology in prostate cancer clinical trials.（转化医学网360zhyx.com）
评论：
共有 1 条评论
-
游客2015-11-20 18:30:42听着开心，患者怎能和你们
加载更多
正在加载没有更早的了